Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort (Multi-Center PAMPA Study)
Brief description of study
Patients with psoriasis (PsO) are at a higher risk of developing psoriatic arthritis (PsA). About 1 in 3 patients with PsO will develop arthritis of the joints or spine, and specifically those added risk factors, including family history of PsA, nail psoriasis, scalp psoriasis and overweight. The purpose of this study is to evaluate the study drug TREMFYA (guselkumab) in high-risk psoriasis patients to study whether it can prevent progression of psoriasis to psoriatic arthritis when compared to placebo and to other standard of care treatment.
Clinical Study Identifier: s20-01158
ClinicalTrials.gov Identifier: NCT05004727
Principal Investigator:
Jose U Scher.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.